Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CARM Carisma Therapeutics

Market Closed 10-04 16:00:00 EDT

0.9450

+0.0150

+1.61%

盘后0.9447

-0.0003-0.03%

19:13 EDT

High0.9620	Low0.9350	Vol39.82K
Open0.9404	D1 Closing0.9300	Amplitude2.90%
Mkt Cap39.26M	Tradable Cap21.27M	Total Shares41.54M
T/O37.60K	T/O Rate0.18%	Tradable Shares22.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CARM","market":"US","secType":"STK","nameCN":"Carisma Therapeutics","latestPrice":0.945,"timestamp":1728072000000,"preClose":0.93,"halted":0,"volume":39817,"hourTrading":{"tag":"盘后","latestPrice":0.9447,"preClose":0.945,"latestTime":"19:13 EDT","volume":1076,"amount":1015.8285,"timestamp":1728083621218},"delay":0,"floatShares":22512694,"shares":41544975,"eps":-1.774969,"marketStatus":"Market Closed","change":0.015,"latestTime":"10-04 16:00:00 EDT","open":0.9404,"high":0.96199,"low":0.935,"amount":37602.215210300004,"amplitude":0.029022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.774969,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1728288000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.93,"preHourTrading":{"tag":"盘前","latestPrice":0.9485,"preClose":0.93,"latestTime":"09:23 EDT","volume":1513,"amount":1434.9357059,"timestamp":1728048196569},"postHourTrading":{"tag":"盘后","latestPrice":0.9447,"preClose":0.945,"latestTime":"19:13 EDT","volume":1076,"amount":1015.8285,"timestamp":1728083621218},"volumeRatio":0.36786186182925307},"requestUrl":"/m/hq/s/CARM","defaultTab":"news","newsList":[{"id":"2472065951","title":"Carisma Therapeutics Announces Upcoming Presentations at SITC 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2472065951","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472065951?lang=en_us&edition=fundamental","pubTime":"2024-10-04 21:05","pubTimestamp":1728047100,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer , taking place in Houston, Texas, November 6 -10, 2024.Details on the poster presentations at SITC 2024 are below:. Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma Publication Number: 329Session Date & Time: Friday, Nov. 8, 2024 Location:Exhibit Halls A B George R. Brown Convention Center. Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aGF3Q8ckRSfUVydORVClCw--~B/aD0xMDQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-therapeutics-announces-upcoming-presentations-130500138.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-announces-upcoming-presentations-130500138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4139","BK4230","BK4080","CARM","SITC","BK4231","CAR"],"gpt_icon":0},{"id":"2467481797","title":"Buy Rating for Carisma Therapeutics Amid Expansion into Autoimmune Treatments with Moderna Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2467481797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467481797?lang=en_us&edition=fundamental","pubTime":"2024-09-13 14:05","pubTimestamp":1726207529,"startTime":"0","endTime":"0","summary":"Jack Allen, an analyst from Robert W. Baird, maintained the Buy rating on Carisma Therapeutics (CARM – Research Report). The associated price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-carisma-therapeutics-amid-expansion-into-autoimmune-treatments-with-moderna-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-carisma-therapeutics-amid-expansion-into-autoimmune-treatments-with-moderna-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARM"],"gpt_icon":0},{"id":"2466430989","title":"Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466430989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466430989?lang=en_us&edition=fundamental","pubTime":"2024-09-10 20:51","pubTimestamp":1725972679,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","BK4585","BK4533","CAR","BK4532","CARM","BK4501","BK4551","MRNA","BK4534","BK4568","BK4548","BK4588"],"gpt_icon":0},{"id":"2466430320","title":"Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466430320","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466430320?lang=en_us&edition=fundamental","pubTime":"2024-09-10 20:51","pubTimestamp":1725972679,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics  said Tuesday it is expanding its collaboration with Moderna  to include the nomination of two targets to treat autoimmune diseases.The companies will develop in vivo chimeric antigen receptor macrophage and monocyte or CAR-M for autoimmune diseases, building on preclinical in vivo CAR-M data in oncology, Carisma said.Carisma said Moderna nominated two autoimmune disease targets under the collaboration, which will use Carisma's CAR-M technology and Moderna's mRNA/LNP platform for the development of in vivo macrophage engineering approaches in the nominated targets.Beyond the two nominated targets, which will be exclusively partnered with Moderna, all rights in autoimmune disease will be retained by Carisma, according to Carisma.Carisma, which will have the responsibility to discover and optimize development candidates, said it will receive research funding and can get development, regulatory and commercial milestone payments, as well as royalties on net sales of an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","MRNA","BK4501","BK4532","BK4568","BK4588","BK4585","CARM","BK4533","BK4548","BK4139","BK4551"],"gpt_icon":1},{"id":"2466543928","title":"BRIEF-Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466543928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466543928?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:41","pubTimestamp":1725968466,"startTime":"0","endTime":"0","summary":"Sept 10  - Carisma Therapeutics Inc   :   * CARISMA AND MODERNA EXPAND COLLABORATION TO DEVELOP TWO IN VIVO CAR-M THERAPIES FOR AUTOIMMUNE DISEASES   * CARISMA THERAPEUTICS INC - MODERNA NOMINATES TWO AUTOIMMUNE DISEASE TARGETS UNDER COLLABORATION   * CARISMA THERAPEUTICS INC - TO HANDLE DISCOVERY, MODERNA TO LEAD CLINICAL DEVELOPMENT   * CARISMA THERAPEUTICS INC - ELIGIBLE FOR MILESTONES AND ROYALTY PAYMENTSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4533","BK4534","BK4548","BK4585","BK4551","BK4588","CAR","BK4139","CARM","MRNA","BK4532","BK4501"],"gpt_icon":0},{"id":"2466782436","title":"Carisma Therapeutics Inc - Moderna Nominates Two Autoimmune Disease Targets Under Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2466782436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466782436?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:30","pubTimestamp":1725967805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA45QW69:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRNA","BK4534","BK4551","BK4568","CARM","BK4532","BK4548","BK4585","BK4501","BK4533","BK4139","BK4588"],"gpt_icon":0},{"id":"2466743678","title":"Carisma Therapeutics Inc - Eligible for Milestones and Royalty Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2466743678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466743678?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:30","pubTimestamp":1725967805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA45QW69:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4139","BK4568","BK4551","BK4501","BK4548","CARM","BK4585","BK4588","MRNA","BK4533","BK4532"],"gpt_icon":0},{"id":"2466367814","title":"Carisma Therapeutics Inc - to Handle Discovery, Moderna to Lead Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2466367814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466367814?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:30","pubTimestamp":1725967805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA45QW69:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4532","BK4548","BK4568","CARM","MRNA","BK4588","BK4501","BK4551","BK4533","BK4139","BK4534"],"gpt_icon":0},{"id":"2466362444","title":"Carisma and Moderna Expand Collaboration to Develop Two in Vivo Car-M Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466362444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466362444?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:30","pubTimestamp":1725967805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240910:nTUA45QW69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4139","BK4585","MRNA","BK4551","BK4588","BK4533","BK4568","BK4532","BK4501","CARM","BK4534"],"gpt_icon":0},{"id":"2466431341","title":"Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2466431341","media":"PR Newswire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466431341?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:30","pubTimestamp":1725967800,"startTime":"0","endTime":"0","summary":"Building on successful pre-clinical invivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases. Moderna nominated two autoimmune disease targets under the collaboration. Carisma is eligible to receive milestones and royalty payments. \"We are excited to expand our collaboration with Moderna into the realm of autoimmune diseases,\" said Steven Kelly, President and Chief Executive Officer ofCarisma. \"The nomination of the two autoimmune targets is a significant milestone in our mission to harness the power of macrophages to treat a broader range of diseases. Our innovative CAR-M technology has the potential to revolutionize the treatment landscape for patients suffering from these debilitating conditions.\". Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We ha","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j16.mEJXcfaJ7O5bFIJAAQ--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j16.mEJXcfaJ7O5bFIJAAQ--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-moderna-expand-collaboration-develop-113000909.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-moderna-expand-collaboration-develop-113000909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Carisma and Moderna Join Forces to Revolutionize Autoimmune Treatment","news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MRNA","BK4534","BK4551","BK4568","CAR","CARM","BK4532","BK4548","BK4585","BK4501","BK4230","BK4022","BK4533","BK4139","BK4588"],"gpt_icon":1},{"id":"2464877780","title":"Carisma Therapeutics to Present at Upcoming Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2464877780","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464877780?lang=en_us&edition=fundamental","pubTime":"2024-09-03 19:30","pubTimestamp":1725363000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc.  , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced thatSteven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences:. Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts, when available, will be archived for a limited time following the event.Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more infor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j16.mEJXcfaJ7O5bFIJAAQ--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j16.mEJXcfaJ7O5bFIJAAQ--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/carisma-therapeutics-present-upcoming-conferences-113000683.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-present-upcoming-conferences-113000683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2459181008","title":"Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459181008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459181008?lang=en_us&edition=fundamental","pubTime":"2024-08-14 00:31","pubTimestamp":1723566704,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insulet (PODD – Research Report), Carisma Therapeu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insulet-podd-carisma-therapeutics-carm-and-recursion-pharmaceuticals-rxrx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insulet-podd-carisma-therapeutics-carm-and-recursion-pharmaceuticals-rxrx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PODD","HCSG","BK4566","CARM","BK4585","BK4539","BK4082","BK4588","BK4548","RXRX","BK4551","BK4137","BK4139"],"gpt_icon":0},{"id":"2459138335","title":"CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2459138335","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459138335?lang=en_us&edition=fundamental","pubTime":"2024-08-14 00:00","pubTimestamp":1723564811,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for CARISMA THERAP is essentially a positive comment on its earnings outlook that could have a favorable impact on","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YliGu3uiWo7T6YkWQuaEpA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62d8c8e05376a18ba1420a1733ffdda4"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therap-carm-upgraded-buy-160011514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CARM"],"gpt_icon":0},{"id":"2458579564","title":"Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458579564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458579564?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:43","pubTimestamp":1723203821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verve Therapeutics (VERV – Research Report), 4D Mole...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verve-therapeutics-verv-4d-molecular-therapeutics-fdmt-and-carisma-therapeutics-carm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verve-therapeutics-verv-4d-molecular-therapeutics-fdmt-and-carisma-therapeutics-carm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FDMT","CARM","VERV","BK4539","HCSG","BK4137","BK4139"],"gpt_icon":0},{"id":"2457315767","title":"Carisma Therapeutics Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2457315767","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457315767?lang=en_us&edition=fundamental","pubTime":"2024-08-08 21:23","pubTimestamp":1723123434,"startTime":"0","endTime":"0","summary":"* Carisma Therapeutics Inc    reported a quarterly adjusted loss of 27 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -49 ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Carisma Therapeutics Inc reports results for the quarter ended in January - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARM"],"gpt_icon":0},{"id":"2457310507","title":"Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2457310507","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457310507?lang=en_us&edition=fundamental","pubTime":"2024-08-08 21:00","pubTimestamp":1723122004,"startTime":"0","endTime":"0","summary":"Carisma Therapeutics Inc.  came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.46, delivering a surprise of -24.32%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.CARISMA THERAP , which belongs to the Zacks Medical - Drugs industry, posted revenues of $9.2 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 151.97%. This compares to year-ago revenues of $3.56 million. The company has topped consensus revenue estimates two times over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/carisma-therapeutics-inc-carm-reports-130004283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CARM"],"gpt_icon":0},{"id":"2457391841","title":"Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2457391841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457391841?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:30","pubTimestamp":1723116605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nTUA2Q74RN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","BK4139"],"gpt_icon":0},{"id":"2457391844","title":"Carisma Therapeutics Q2 Net Income USD -11.162 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2457391844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457391844?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:30","pubTimestamp":1723116604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nPLX94D2FC:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CARM","USD","BK4139"],"gpt_icon":0},{"id":"2457391381","title":"Carisma Therapeutics Q2 Operating Income USD -11.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2457391381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457391381?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:30","pubTimestamp":1723116604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nPLX94D2FC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["USD","BK4139","CARM"],"gpt_icon":0},{"id":"2457913483","title":"Carisma Therapeutics Q2 Pretax Profit USD -11.162 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2457913483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457913483?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:30","pubTimestamp":1723116604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nPLX94D2FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","USD","CARM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sesenbio.com","stockEarnings":[{"period":"1week","weight":-0.0644},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.1783},{"period":"6month","weight":-0.4808},{"period":"1year","weight":-0.7842},{"period":"ytd","weight":-0.6775}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.04},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.3498},{"period":"ytd","weight":0.2055}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.118068},{"month":2,"riseRate":0.3,"avgChangeRate":0.03966},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.09024},{"month":4,"riseRate":0.545455,"avgChangeRate":0.307249},{"month":5,"riseRate":0.545455,"avgChangeRate":0.110205},{"month":6,"riseRate":0.727273,"avgChangeRate":0.139785},{"month":7,"riseRate":0.181818,"avgChangeRate":0.036568},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.01952},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.081936},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.066869},{"month":11,"riseRate":0.5,"avgChangeRate":0.024269},{"month":12,"riseRate":0.5,"avgChangeRate":-0.004255}],"exchange":"NASDAQ","name":"Carisma Therapeutics","nameEN":"Carisma Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Carisma Therapeutics(CARM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Carisma Therapeutics,CARM,Carisma Therapeutics股票,Carisma Therapeutics股票老虎,Carisma Therapeutics股票老虎国际,Carisma Therapeutics行情,Carisma Therapeutics股票行情,Carisma Therapeutics股价,Carisma Therapeutics股市,Carisma Therapeutics股票价格,Carisma Therapeutics股票交易,Carisma Therapeutics股票购买,Carisma Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Carisma Therapeutics(CARM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Carisma Therapeutics(CARM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction